keyword
MENU ▼
Read by QxMD icon Read
search

American society of hematology

keyword
https://www.readbyqxmd.com/read/29768480/internal-medicine-trainees-knowledge-and-confidence-in-using-the-american-society-of-hematology-choosing-wisely-guidelines-in-hemostasis-thrombosis-and-non-malignant-hematology
#1
Ariela L Marshall, Sarah Jenkins, Amy S Oxentenko, Alfred I Lee, Mark D Siegel, Joel T Katz, Jatin M Vyas, John Del Valle, Joseph R Mikhael
BACKGROUND: Several specialty societies participate in the Choosing Wisely (CW) campaign in an attempt to reduce waste in health care spending. We surveyed internal medicine (IM) residents with an objective of classifying knowledge of and confidence in using the American Society of Hematology (ASH) CW principles in hemostasis, thrombosis, and non-malignant hematology. METHODS: Multi-institutional study of IM residents at 5 academic training programs in the United States...
2018: PloS One
https://www.readbyqxmd.com/read/29742278/conditional-relative-survival-among-long-term-survivors-of-adolescent-and-young-adult-cancers
#2
Chelsea Anderson, Andrew B Smitherman, Hazel B Nichols
BACKGROUND: Many studies have examined long-term outcomes after childhood cancer, but few address outcomes for adolescent and young adult (AYA; those aged 15-39 years) cancer survivors. Conditional survival reflects changing mortality risk with time since cancer diagnosis and is a useful measure for planning long-term follow-up care. METHODS: Using the Surveillance, Epidemiology, and End Results registry 9 database, the authors identified a cohort of AYA patients diagnosed with a first malignant cancer between 1973 and 2009 and followed through 2014...
May 9, 2018: Cancer
https://www.readbyqxmd.com/read/29742098/advances-in-aggressive-lymphoma-from-the-2017-american-society-of-hematology-annual-meeting-and-exposition-commentary
#3
Frederick L Locke, Faysal Haroun
No abstract text is available yet for this article.
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742097/advances-in-aggressive-lymphoma-from-the-2017-american-society-of-hematology-annual-meeting-and-exposition
#4
(no author information available yet)
No abstract text is available yet for this article.
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742096/highlights-in-lymphoma-from-the-2017-american-society-of-hematology-meeting-commentary
#5
Craig H Moskowitz
No abstract text is available yet for this article.
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742095/highlights-in-lymphoma-from-the-2017-american-society-of-hematology-annual-meeting-and-exposition
#6
(no author information available yet)
No abstract text is available yet for this article.
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742092/highlights-in-chronic-lymphocytic-leukemia-from-the-2017-american-society-of-hematology-annual-meeting-commentary
#7
Susan M O'Brien
No abstract text is available yet for this article.
January 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742091/highlights-in-chronic-lymphocytic-leukemia-from-the-2017-american-society-of-hematology-annual-meeting-and-exposition
#8
(no author information available yet)
No abstract text is available yet for this article.
January 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742090/highlights-in-myeloproliferative-neoplasms-from-the-2017-american-society-of-hematology-annual-meeting-commentary
#9
Srdan Verstovsek
No abstract text is available yet for this article.
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742089/highlights-in-myeloproliferative-neoplasms-from-the-2017-american-society-of-hematology-annual-meeting-and-exposition
#10
(no author information available yet)
No abstract text is available yet for this article.
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29727916/characteristics-and-outcomes-of-patients-with-hematologic-malignancies-receiving-chemotherapy-in-the-intensive-care-unit
#11
Stephen M Pastores, Debra A Goldman, David J Shaz, Natalie Kostelecky, Ryan J Daley, Tim J Peterson, Kay See Tan, Neil A Halpern
BACKGROUND: The objective of this study was to evaluate the short-term and long-term outcomes of adult patients with hematologic malignancies who received chemotherapy in the intensive care unit (ICU). METHODS: This was a retrospective, single-center study comparing the outcomes of patients with hematologic malignancies who received chemotherapy in the ICU with a matched cohort of ICU patients who did not receive chemotherapy. Conditional logistic regression and shared-frailty Cox regression were used to assess short-term (ICU and hospital) mortality and death by 12 months after hospital discharge, respectively...
May 4, 2018: Cancer
https://www.readbyqxmd.com/read/29726788/outcomes-in-obese-patients-undergoing-induction-therapy-for-acute-leukemia
#12
Lauren Dombrowski, Leila Mohassel
Obesity continues to be a growing epidemic in the United States. Guidelines published by American Society of Clinical Oncology in 2012 recommend dosing chemotherapy using actual body weight. However, the guidelines do not provide guidance for patients with hematologic malignancies. The objective of this study was to evaluate outcomes in obese patients undergoing induction chemotherapy for acute leukemia versus nonobese patients using actual body weight dosing. This single center retrospective chart review from November 2012 to August 2016 evaluated newly diagnosed leukemia patients who received induction chemotherapy dosed on actual body weight...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29723393/phase-2-trial-of-bortezomib-in-combination-with-rituximab-plus-hyperfractionated-cyclophosphamide-vincristine-doxorubicin-and-dexamethasone-alternating-with-bortezomib-rituximab-methotrexate-and-cytarabine-for-untreated-mantle-cell-lymphoma
#13
Jorge E Romaguera, Michael Wang, Lei Feng, Luis E Fayad, Frederick Hagemeister, Peter McLaughlin, M Alma Rodriguez, Michelle Fanale, Robert Orlowski, Larry W Kwak, Sattva Neelapu, Yasuhiro Oki, Barbara Pro, Anas Younes, Felipe Samaniego, Nathan Fowler, Kimberly Hartig, Marisa Valentinetti, Judy Smith, Peggy Ford, Adam Naig, L Jeffrey Medeiros, Hagop M Kantarjian, Andre Goy
BACKGROUND: Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials with known effective agents. METHODS: This is a report of a prospective phase 2 trial of bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-hyperCVAD)/rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) for 95 patients with newly diagnosed MCL...
May 3, 2018: Cancer
https://www.readbyqxmd.com/read/29682723/improving-the-detection-of-patients-with-inherited-predispositions-to-hematologic-malignancies-using-next-generation-sequencing-based-leukemia-prognostication-panels
#14
REVIEW
Courtney D DiNardo, Mark J Routbort, Sarah A Bannon, Christopher B Benton, Koichi Takahashi, Steve M Kornblau, Rajyalakshmi Luthra, Rashmi Kanagal-Shamanna, L Jeffrey Medeiros, Guillermo Garcia-Manero, Hagop Kantarjian, P Andrew Futreal, Funda Meric-Bernstam, Keyur P Patel
Recognizing and referring patients with possible inherited cancer predisposition syndromes for appropriate genetic evaluation and testing provides insights into optimal patient treatment approaches and also can provide education and testing opportunities for family members. Next-generation sequencing (NGS)-based, targeted genotyping for somatic mutations is increasingly used in the diagnosis, prognostication, and treatment selection for patients with hematologic malignancies. However, certain mutations that may be somatically acquired can also be present as germline mutations in some individuals and families...
April 6, 2018: Cancer
https://www.readbyqxmd.com/read/29682694/the-american-society-of-hematology-ash-medical-educators-institute-a-pilot-faculty-development-project-for-hematology-educators
#15
Jennifer C Kesselheim, Charles P Clayton, Josel Fritz, Roy E Smith, Scott D Gitlin, Erin Reid, Kenneth S Zuckerman, Marc J Kahn
Clinician educators at academic medical centers often lack the community, mentorship, and faculty development to support their missions around education scholarship and teaching. Inadequate support for clinician educators can lead to professional dissatisfaction and slowed academic advancement. In 2014, ASH conducted a needs assessment of medical school hematology course directors, hematology-oncology fellowship program directors, and other ASH members identified as educators to determine this community's desire for faculty development in medical education...
April 22, 2018: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/29660822/managing-work-and-cancer-treatment-experiences-among-survivors-of-hematological-cancer
#16
Maria D Thomson, Laura A Siminoff
BACKGROUND: The current study was performed to characterize the employment status of survivors of hematological cancer who have an informal caregiver from the time of diagnosis through the first 6 months of treatment. METHODS: Using a mixed methods approach, semistructured interviews with survivors of hematological cancer were conducted within 6 months of the initiation of cancer treatment. Interviews assessed cancer treatment status, barriers and facilitators to employment, financial and insurance status, and relationship with the primary caregiver...
April 16, 2018: Cancer
https://www.readbyqxmd.com/read/29660201/universal-screening-for-hepatitis-c-a-needed-approach-in-patients-with-hematologic-malignancies
#17
Georgios Angelidakis, Jessica P Hwang, Dima Dandachi, Minas P Economides, Jeff Hosry, Bruno P Granwehr, Harrys A Torres
There have been no large studies on the prevalence of hepatitis C virus antibody (anti-HCV) and the optimal HCV screening strategy in patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients. On the basis of the limited available evidence, the American Society for Blood and Marrow Transplantation and European Conference on Infection in Leukemia recommend universal screening. We aimed to determine the prevalence of anti-HCV and to compare the effectiveness of universal HCV screening versus risk-factor-based and 1945-1965 birth-cohort-based screening at the largest tertiary cancer center in the United States...
April 16, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29603868/american-society-of-pediatric-hematology-oncology-aspho-david-l-lawrence-convention-center-pittsburgh-pa-may-2-5-2018
#18
(no author information available yet)
No abstract text is available yet for this article.
June 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29589223/an-analysis-of-the-inclusion-of-medications-considered-potentially-inappropriate-in-older-adults-in-chemotherapy-templates-for-hematologic-malignancies-one-recommendation-for-all
#19
Amy Zhou, Holly M Holmes, Arti Hurria, Tanya M Wildes
BACKGROUND: There remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Raising awareness among healthcare providers regarding the frequency of their use and potential toxicities may help to minimize the risks to patients. OBJECTIVE: The aim of this study was to evaluate the frequency of six specific classes of medications considered PIMs by the American Geriatrics Society Beers Criteria that are commonly included in the National Comprehensive Cancer Network (NCCN) chemotherapy order templates for hematologic malignancies...
March 27, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29576386/multiple-myeloma-clinical-updates-from-the-american-society-of-hematology-annual-meeting-2017
#20
REVIEW
Evangelos Terpos
The novel clinical data for myeloma that were presented in the 2017 Annual Meeting of the American Society of Hematology are summarized here. Studies with curative approach (CESAR) or prolonging progression-free survival (CENTAURUS) for patients with high-risk smoldering multiple myeloma (SMM) are described. Updated data from large phase III studies for patients with newly diagnosed MM (NDMM) who are eligible for autologous stem cell transplantation (ASCT) (EMN02, MRC XI) are described, along with the results of studies using novel anti-myeloma drug combinations for induction, consolidation, and maintenance as first-line therapy...
March 1, 2018: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
12147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"